ReviewProteomes2022
Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.
Review in Proteomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 5 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Management paradigm for ovarian neuroendocrine carcinoma: a systematic review.Journal of ovarian research · 2025Pooled it
- The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.Journal of ovarian research · 2022Pooled it
- Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis.Frontiers in oncology · 2022Pooled it
- The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Prognostic Factors of Advanced Ovarian Cancer in the Era of HIPEC: A Multicenter Retrospective Study from an ESGO-Certified Center and an ESPSO-Certified Center.Biomedicines · 2026Article
- Evaluation of drug options for epithelial ovarian cancer (EOC) treatment using the analytical hierarchy process improves decision-making transparency.Discover oncology · 2025Article
- Tβ4-17 peptide enhances the chemo-sensitivity of ovarian cancer cells to DDP by affecting NF-κB signaling pathway.Medical oncology (Northwood, London, England) · 2025Article
- Redefining Risk, Biomarkers, and Precision Therapy for Hereditary Ovarian Cancer: A Review.ACS omega · 2025Review
- Ovarian Cancer: Multi-Omics Data Integration.International journal of molecular sciences · 2025Review
- Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Oncogene · 2025Review
- Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.Journal of ovarian research · 2024Article
- Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma.Journal of Zhejiang University. Science. B · 2024Article
- Skin metastasis from ovarian cancer with somatic BRCA1 mutation: A case report and literature review.Oncology letters · 2024Article
- Exploration and prognostic analysis of two types of high-risk ovarian cancers: clear cell vs. serous carcinoma: a population-based study.Journal of ovarian research · 2024Article
- Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer.Cancer medicine · 2024Article
- miR‑146a‑5p and miR‑191‑5p as novel diagnostic marker candidates for ovarian clear cell carcinoma.Molecular and clinical oncology · 2024Article
- Article
- TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.Future oncology (London, England) · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The patients present an advanced stage at diagnosis. This heterogeneous disease has distinguishable etiology and molecular biology. Next-generation sequencing changed clinical diagnostic testing, allowing assessment of multiple genes, simultaneously, in a faster and cheaper manner than sequential single gene analysis. Technologies of proteomics, such as mass spectrometry (MS) and protein array analysis, have advanced the dissection of the underlying molecular signaling events and the proteomic characterization of OC. Proteomics analysis of OC, as well as their adaptive responses to therapy, can uncover new therapeutic choices, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is an urgent need to better understand how the genomic and epigenomic heterogeneity intrinsic to OC is reflected at the protein level, and how this information could potentially lead to prolonged survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.